Myriad Genetics Company Profile (NASDAQ:MYGN)

About Myriad Genetics (NASDAQ:MYGN)

Myriad Genetics logoMyriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Research Services
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:MYGN
  • CUSIP: 62855J10
  • Web:
  • Market Cap: $1.39 billion
  • Outstanding Shares: 68,118,000
Average Prices:
  • 50 Day Moving Avg: $19.89
  • 200 Day Moving Avg: $18.16
  • 52 Week Range: $15.15 - $35.35
  • Trailing P/E Ratio: 43.74
  • Foreward P/E Ratio: 18.95
  • P/E Growth: -3.16
Sales & Book Value:
  • Annual Revenue: $757.3 million
  • Price / Sales: 1.84
  • Book Value: $10.99 per share
  • Price / Book: 1.86
  • EBIDTA: $122.6 million
  • Net Margins: 8.08%
  • Return on Equity: 12.02%
  • Return on Assets: 8.35%
  • Debt-to-Equity Ratio: 0.28%
  • Current Ratio: 4.13%
  • Quick Ratio: 3.51%
  • Average Volume: 1.19 million shs.
  • Beta: 0.26
  • Short Ratio: 15.06

Frequently Asked Questions for Myriad Genetics (NASDAQ:MYGN)

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) issued its quarterly earnings data on Tuesday, May, 2nd. The company reported $0.27 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.24 by $0.03. The firm earned $196.90 million during the quarter, compared to analyst estimates of $188.89 million. Myriad Genetics had a return on equity of 12.02% and a net margin of 8.08%. View Myriad Genetics' Earnings History.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics issued an update on its fourth quarter earnings guidance on Tuesday, May, 2nd. The company provided earnings per share guidance of $0.26-0.28 for the period, compared to the Thomson Reuters consensus estimate of $0.26. The company issued revenue guidance of $192-194 million, compared to the consensus revenue estimate of $188.50 million.

Where is Myriad Genetics' stock going? Where will Myriad Genetics' stock price be in 2017?

12 equities research analysts have issued 1-year price objectives for Myriad Genetics' shares. Their predictions range from $16.00 to $32.00. On average, they anticipate Myriad Genetics' share price to reach $21.82 in the next year. View Analyst Ratings for Myriad Genetics.

What are analysts saying about Myriad Genetics stock?

Here are some recent quotes from research analysts about Myriad Genetics stock:

  • 1. Cowen and Company analysts commented, "The FDA approved Tesaro's niraprarib (Zejula) yesterday. This approval was not limited to mutational status, and therefore does not require MYGN's myChoice HRD test. This outcome is consistent with our thoughts since last June, and as a result has limited impact to our MYGN financial forecast." (3/28/2017)
  • 2. According to Zacks Investment Research, "Ahead of its second quarter 2017 report, in the last three months, Myriad’s share price trend was neck and neck with respect to that of the Medical-Biomed/Genetics Market trend. However the trend got disturbed post its mixed fiscal 2017 first quarter earnings with earnings missing the Zacks Consensus Estimate and revenues ahead of the mark. The year-over-year drop in revenues was due to ongoing sluggish hereditary cancer test performance. Competitive landscape and currency headwinds remain the major concerns. However, Myriad made progress with its recently released product line. Strong growth was also observed in both Prolaris and Vectra DA testing revenues. Genesight, Myriad’s second-largest product’s revenues and volumes exceeded expectations in its first full quarter. The integration of recently acquired Assurex health has also initiated, which should help Myriad achieve break-even earnings in the first half of fiscal 2018." (2/1/2017)

Are investors shorting Myriad Genetics?

Myriad Genetics saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 24,825,404 shares, an increase of 0.2% from the April 13th total of 24,878,238 shares. Based on an average daily volume of 780,305 shares, the short-interest ratio is presently 31.8 days. Approximately 37.1% of the shares of the company are sold short.

Who are some of Myriad Genetics' key competitors?

Who owns Myriad Genetics stock?

Myriad Genetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (14.57%), BlackRock Inc. (14.01%), Vanguard Group Inc. (9.18%), Camber Capital Management LLC (6.35%), D. E. SHAW & COMPANY , L.P. (5.00%) and State Street Corp (4.66%). Company insiders that own Myriad Genetics stock include Alexander Ford, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard M Marsh, S Louise Phanstiel and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

Who sold Myriad Genetics stock? Who is selling Myriad Genetics stock?

Myriad Genetics' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, State Street Corp, Baillie Gifford & Co., Acadian Asset Management LLC, KBC Group NV, Cornerstone Capital Management Holdings LLC. and JPMorgan Chase & Co.. Company insiders that have sold Myriad Genetics stock in the last year include Alexander Ford and John T Henderson. View Insider Buying and Selling for Myriad Genetics.

Who bought Myriad Genetics stock? Who is buying Myriad Genetics stock?

Myriad Genetics' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, Vanguard Group Inc., Bank of New York Mellon Corp, Principal Financial Group Inc., First Trust Advisors LP, Ameriprise Financial Inc. and Camber Capital Management LLC. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, Mark Christopher Capone and Ralph L Mcdade. View Insider Buying and Selling for Myriad Genetics.

How do I buy Myriad Genetics stock?

Shares of Myriad Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Myriad Genetics stock cost?

One share of Myriad Genetics stock can currently be purchased for approximately $20.47.

Analyst Ratings

Consensus Ratings for Myriad Genetics (NASDAQ:MYGN) (?)
Ratings Breakdown: 3 Sell Ratings, 8 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 1.83)
Consensus Price Target: $21.82 (6.59% upside)

Analysts' Ratings History for Myriad Genetics (NASDAQ:MYGN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/8/2017Deutsche Bank AGBoost Price TargetSell$15.00 -> $20.00LowView Rating Details
5/3/2017Jefferies Group LLCReiterated RatingHold$18.00 -> $21.00MediumView Rating Details
3/28/2017Cowen and CompanyReiterated RatingMarket Perform$19.00MediumView Rating Details
3/13/2017StephensUpgradeEqual Weight -> Overweight$20.00MediumView Rating Details
2/8/2017Piper Jaffray CompaniesBoost Price Target$22.00N/AView Rating Details
2/8/2017Ladenburg Thalmann Financial ServicesUpgradeSell -> NeutralN/AView Rating Details
12/27/2016Barclays PLCReiterated RatingEqual Weight$22.00N/AView Rating Details
10/10/2016Bank of America CorpReiterated RatingSellN/AView Rating Details
8/21/2016Wells Fargo & CoUpgradeMarket Perform -> OutperformN/AView Rating Details
8/10/2016Morgan StanleyLower Price TargetUnderweight$25.00 -> $21.00N/AView Rating Details
8/10/2016GabelliDowngradeBuy -> Hold$46.00 -> $32.00N/AView Rating Details
8/10/2016MizuhoLower Price TargetNeutral$34.00 -> $22.00N/AView Rating Details
5/4/2016Leerink SwannReiterated RatingMarket Perform$44.00 -> $41.00N/AView Rating Details
5/4/2016Avondale PartnersLower Price TargetMarket Outperform$50.00 -> $47.00N/AView Rating Details
3/23/2016Goldman Sachs Group IncBoost Price Target$40.00N/AView Rating Details
9/20/2015William BlairReiterated RatingBuyN/AView Rating Details
8/12/2015JMP SecuritiesLower Price TargetMarket Outperform$46.00 -> $40.00N/AView Rating Details
5/28/2015Credit Suisse Group AGReiterated RatingUnderperformN/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for Myriad Genetics (NASDAQ:MYGN)
Earnings by Quarter for Myriad Genetics (NASDAQ:MYGN)
Earnings History by Quarter for Myriad Genetics (NASDAQ:MYGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q3 2017$0.24$0.27$188.89 million$196.90 millionViewListenView Earnings Details
2/7/2017Q2 2017$0.24$0.26$189.72 million$196.50 millionViewListenView Earnings Details
11/1/2016Q117$0.26$0.23$172.31 million$177.50 millionViewN/AView Earnings Details
8/9/2016Q416$0.38$0.36$187.95 million$186.50 millionViewN/AView Earnings Details
5/3/2016Q316$0.38$0.41$185.08 million$190.50 millionViewN/AView Earnings Details
2/2/2016Q216$0.41$0.45$189.99 million$193.30 millionViewN/AView Earnings Details
11/3/2015Q116$0.35$0.41$177.89 million$183.50 millionViewN/AView Earnings Details
8/11/2015Q415$0.42$0.41$187.81 million$189.90 millionViewListenView Earnings Details
5/5/2015Q315$0.39$0.40$183.30 million$180.00 millionViewListenView Earnings Details
2/3/2015Q215$0.35$0.40$183.41 million$184.40 millionViewListenView Earnings Details
11/4/2014Q115$0.33$0.25$175.00 million$168.84 millionViewListenView Earnings Details
8/12/2014Q414$0.46$0.48$187.68 million$188.80 millionViewListenView Earnings Details
5/6/2014Q314$0.45$0.60$175.23 million$182.92 millionViewListenView Earnings Details
2/4/2014Q214$0.46$0.66$176.02 million$204.06 millionViewListenView Earnings Details
11/5/2013Q114$0.46$0.68$167.64 million$202.50 millionViewN/AView Earnings Details
8/13/2013Q4 2013$0.44$0.53$159.87 million$174.10 millionViewN/AView Earnings Details
5/7/2013Q3 2013$0.39$0.46$148.25 million$156.40 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.38$0.42$143.71 million$140.70 millionViewN/AView Earnings Details
11/5/2012Q113$0.32$0.36$129.84 million$133.40 millionViewN/AView Earnings Details
8/14/2012$0.34$0.34ViewN/AView Earnings Details
5/1/2012$0.32$0.34ViewN/AView Earnings Details
1/31/2012$0.31$0.33ViewN/AView Earnings Details
11/1/2011$0.27$0.29ViewN/AView Earnings Details
8/9/2011$0.29$0.30ViewN/AView Earnings Details
5/3/2011$0.25$0.31ViewN/AView Earnings Details
1/27/2011$0.26$0.26ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Myriad Genetics (NASDAQ:MYGN)
2017 EPS Consensus Estimate: $1.25
2018 EPS Consensus Estimate: $1.06
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.25$0.42$0.31
Q2 20173$0.23$0.46$0.33
Q3 20173$0.24$0.43$0.31
Q4 20173$0.26$0.38$0.30
Q1 20182$0.23$0.26$0.25
Q2 20182$0.26$0.27$0.27
Q3 20182$0.26$0.28$0.27
Q4 20182$0.27$0.29$0.28
(Data provided by Zacks Investment Research)


Dividend History for Myriad Genetics (NASDAQ:MYGN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Myriad Genetics (NASDAQ:MYGN)
Insider Ownership Percentage: 6.20%
Insider Trades by Quarter for Myriad Genetics (NASDAQ:MYGN)
Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)
Insider Trades by Quarter for Myriad Genetics (NASDAQ:MYGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/23/2017John T HendersonDirectorBuy6,000$18.66$111,960.00View SEC Filing  
9/12/2016John T HendersonDirectorSell30,000$20.49$614,700.00View SEC Filing  
8/19/2016Mark Christopher CaponeInsiderBuy10,000$21.24$212,400.00View SEC Filing  
8/12/2016Ralph L McdadeInsiderBuy1,000$21.49$21,490.00View SEC Filing  
6/21/2016Alexander FordInsiderSell18,637$30.87$575,324.19View SEC Filing  
4/6/2016Gary A KingVPSell15,000$39.03$585,450.00View SEC Filing  
4/1/2016Gary A KingVPSell15,000$38.12$571,800.00View SEC Filing  
12/11/2015Walter Phd GilbertDirectorSell5,000$42.23$211,150.00View SEC Filing  
12/8/2015S. Louise PhanstielDirectorSell5,000$44.00$220,000.00View SEC Filing  
11/5/2015Heinrich DreismannDirectorSell60,000$44.44$2,666,400.00View SEC Filing  
11/4/2015Richard M. MarshVPSell35,000$44.50$1,557,500.00View SEC Filing  
10/28/2015Gary A. KingVPSell10,000$42.82$428,200.00View SEC Filing  
10/28/2015Jerry S. LanchburyinsiderSell50,962$41.86$2,133,269.32View SEC Filing  
10/27/2015Jerry S. LanchburyinsiderSell24,767$41.80$1,035,260.60View SEC Filing  
9/17/2015Jerry S. LanchburyinsiderSell60,270$39.89$2,404,170.30View SEC Filing  
9/16/2015Richard M. MarshVPSell35,000$41.25$1,443,750.00View SEC Filing  
9/14/2015Gary A. KingVPSell14,562$39.41$573,888.42View SEC Filing  
9/3/2015Gary A. KingVPSell25,438$39.41$1,002,511.58View SEC Filing  
9/2/2015Gary A. KingVPSell15,000$38.23$573,450.00View SEC Filing  
8/28/2015Gary A. KingVPSell30,000$35.73$1,071,900.00View SEC Filing  
11/3/2014Gary A KingVPSell6,568$39.95$262,391.60View SEC Filing  
9/30/2014James S EvansCFOSell21,850$38.99$851,931.50View SEC Filing  
9/24/2014James S EvansCFOSell8,790$37.98$333,844.20View SEC Filing  
9/23/2014James S EvansCFOSell110,463$37.89$4,185,443.07View SEC Filing  
7/14/2014Peter D MeldrumInsiderSell24,000$39.50$948,000.00View SEC Filing  
6/5/2014John T HendersonDirectorSell5,000$35.70$178,500.00View SEC Filing  
5/9/2014Ronald RogersVPSell12,500$36.01$450,125.00View SEC Filing  
4/30/2014Richard MarshVPSell30,000$41.80$1,254,000.00View SEC Filing  
4/23/2014Richard MarshVPSell31,516$39.80$1,254,336.80View SEC Filing  
4/16/2014Richard MarshVPSell28,484$39.80$1,133,663.20View SEC Filing  
4/7/2014Jayne HartVPSell79,000$40.90$3,231,100.00View SEC Filing  
4/2/2014James EvansCFOSell80,000$40.00$3,200,000.00View SEC Filing  
4/2/2014Peter MeldrumInsiderSell55,000$39.57$2,176,350.00View SEC Filing  
3/19/2014Peter MeldrumInsiderSell55,000$37.00$2,035,000.00View SEC Filing  
3/17/2014Peter MeldrumInsiderSell55,000$35.15$1,933,250.00View SEC Filing  
3/12/2014Richard MarshVPSell50,000$34.37$1,718,500.00View SEC Filing  
2/26/2014Walter Phd GilbertDirectorSell30,000$37.58$1,127,400.00View SEC Filing  
2/25/2014Mark Christopher CaponeInsiderSell95,250$37.83$3,603,307.50View SEC Filing  
2/24/2014Gary KingVPSell20,000$38.00$760,000.00View SEC Filing  
2/20/2014James EvansCFOSell30,000$36.01$1,080,300.00View SEC Filing  
2/20/2014Robert Gardner HarrisonInsiderSell17,554$36.22$635,805.88View SEC Filing  
2/19/2014Richard MarshVPSell34,676$34.71$1,203,603.96View SEC Filing  
2/19/2014Walter Phd GilbertDirectorSell60,000$34.48$2,068,800.00View SEC Filing  
2/18/2014Gary KingVPSell25,000$34.74$868,500.00View SEC Filing  
2/18/2014Heinrich DreismannDirectorSell30,000$35.00$1,050,000.00View SEC Filing  
2/14/2014Richard MarshVPSell20,960$31.50$660,240.00View SEC Filing  
2/12/2014Robert Gardner HarrisonInsiderSell13,707$30.74$421,353.18View SEC Filing  
2/10/2014Mark Christopher CaponeInsiderSell87,500$32.07$2,806,125.00View SEC Filing  
2/7/2014James EvansCFOSell35,000$33.04$1,156,400.00View SEC Filing  
2/5/2014Peter MeldrumInsiderSell123,940$31.10$3,854,534.00View SEC Filing  
11/8/2013James EvansCFOSell8,072$26.50$213,908.00View SEC Filing  
11/8/2013Peter MeldrumInsiderSell31,784$26.50$842,276.00View SEC Filing  
6/13/2013Robert Gardner HarrisonInsiderSell31,498$36.17$1,139,282.66View SEC Filing  
5/16/2013Mark Christopher CaponeInsiderSell79,999$33.23$2,658,366.77View SEC Filing  
5/14/2013Peter D MeldrumInsiderSell15,000$34.00$510,000.00View SEC Filing  
5/10/2013Heinrich DreismannDirectorSell30,000$31.16$934,800.00View SEC Filing  
5/10/2013Peter D MeldrumInsiderSell75,960$31.99$2,429,960.40View SEC Filing  
5/10/2013Richard M MarshVPSell48,192$33.00$1,590,336.00View SEC Filing  
10/4/2012Jerry S LanchburyInsiderSell3,900$28.50$111,150.00View SEC Filing  
10/3/2012Jerry S LanchburyInsiderSell3,000$28.50$85,500.00View SEC Filing  
9/14/2012Peter D MeldrumInsiderSell20,000$27.60$552,000.00View SEC Filing  
9/13/2012James S EvansCFOSell5,494$27.10$148,887.40View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Myriad Genetics (NASDAQ:MYGN)
Latest Headlines for Myriad Genetics (NASDAQ:MYGN)
DateHeadline logoETFs with exposure to Myriad Genetics, Inc. : May 22, 2017 - May 22 at 6:00 PM logoMyriad Genetics (MYGN) to Present Seven Studies at ASCO - May 19 at 11:21 AM logoMyriad Genetics (MYGN) to Present Seven Studies at ASCO - - May 18 at 8:19 AM logoMyriad Genetics to Present Seven Studies at the 2017 American Society of Clinical Oncology Annual Meeting - May 18 at 8:19 AM logoMyriad Genetics to Present Seven Studies at the 2017 American Society of Clinical Oncology Annual Meeting - May 18 at 7:33 AM logoMyriad Genetics (MYGN) Says Data Shows Prolaris Test Accurately Predicts 10-Year Risk of Metastases in Men Treated for Prostate Cancer - May 13 at 8:41 AM logoMyriad Genetics’ Prolaris® Test Accurately Predicts the 10-Year Risk of Metastases in Men Treated for Prostate Cancer - May 12 at 7:21 PM logo$193.54 Million in Sales Expected for Myriad Genetics, Inc. (MYGN) This Quarter - May 11 at 12:42 PM logoFY2017 EPS Estimates for Myriad Genetics, Inc. (MYGN) Boosted by William Blair - May 11 at 11:12 AM logoMyriad Genetics, Inc. (MYGN) Forecasted to Earn Q1 2018 Earnings of $0.23 Per Share - May 10 at 1:08 PM logoETFs with exposure to Myriad Genetics, Inc. : May 9, 2017 - May 9 at 6:22 PM logo$0.26 Earnings Per Share Expected for Myriad Genetics, Inc. (MYGN) This Quarter - May 9 at 8:12 AM logoMyriad Genetics, Inc. (MYGN) Rating Reiterated by Deutsche Bank AG - May 8 at 6:00 PM logoMyriad Genetics, Inc. :MYGN-US: Earnings Analysis: Q3, 2017 By the Numbers : May 8, 2017 - May 8 at 12:25 PM logoMyriad Genetics to Present Results from Four Studies at the American Urological Association 2017 Annual Meeting - GlobeNewswire (press release) - May 5 at 7:02 PM logoMyriad Genetics (MYGN) Tops Q3 Earnings & Sales, Tweaks View - Yahoo Finance - May 5 at 7:02 PM logoQ4 2017 EPS Estimates for Myriad Genetics, Inc. (MYGN) Reduced by Jefferies Group - May 5 at 4:16 PM logoMyriad Genetics to Present Results from Four Studies at the American Urological Association 2017 Annual Meeting - May 5 at 9:22 AM logoAnalysts Offer Predictions for Myriad Genetics, Inc.'s FY2018 Earnings (MYGN) - May 4 at 7:06 PM logoFY2017 Earnings Forecast for Myriad Genetics, Inc. (MYGN) Issued By Jefferies Group - May 4 at 3:04 PM logoMyriad Genetics, Inc. breached its 50 day moving average in a Bullish Manner : MYGN-US : May 4, 2017 - May 4 at 11:28 AM logoMyriad Genetics, Inc. (MYGN) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - May 4 at 1:05 AM logoMyriad Genetics, Inc. (MYGN) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS - May 4 at 12:26 AM logoMyriad Genetics, Inc. (MYGN) Given Hold Rating at Jefferies Group LLC - May 3 at 10:56 PM logoSomewhat Positive News Coverage Very Likely to Impact Myriad Genetics (MYGN) Stock Price - May 3 at 9:36 PM logoMyriad Genetics, Inc. (MYGN) Posts Earnings Results, Beats Estimates By $0.03 EPS - May 3 at 9:30 PM logoMyriad Genetics Increases Annual Revenue Guidance, Narrows Adj. EPS Guidance - May 3 at 5:45 PM logoMyriad Genetics shares jump on earnings beat, outlook - May 3 at 5:45 PM logoHere's Why Myriad Genetics Rose as Much as 16% This Morning - May 3 at 5:45 PM logoHere's Why Myriad Genetics Rose as Much as 16% This Morning - May 3 at 2:51 PM logoMyriad Genetics, Inc. (MYGN) Given Consensus Recommendation of "Hold" by Analysts - May 3 at 10:43 AM logoEdited Transcript of MYGN earnings conference call or presentation 2-May-17 8:30pm GMT - May 3 at 8:19 AM logoMyriad Genetics, Inc. (MYGN) Issues Q4 Earnings Guidance - May 2 at 7:42 PM logoMyriad tops Street 3Q forecasts - May 2 at 5:45 PM logoMyriad Genetics (MYGN) Receives News Impact Score of 0.39 - April 29 at 9:15 PM logoTechnical Roundup on Research Services Stocks -- Myriad Genetics, QIAGEN, INC Research, and Bioanalytical Systems - PR Newswire (press release) - April 27 at 7:14 PM logoMyriad Genetics (MYGN), Clovis (CLVS) Enter Pact for Use of BRACAnalysis CDx Test to Identify Patients with ... - - April 27 at 9:51 AM logoMyriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with Germline BRCA Mutations for Rubraca® (rucaparib) Treatment - April 27 at 9:51 AM logoMyriad Genetics (MYGN) Receives Media Impact Rating of 0.24 - April 26 at 10:36 PM logoCan Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings? - April 24 at 2:56 PM logoMyriad Genetics (MYGN) Receives Daily Media Sentiment Rating of 0.18 - April 23 at 10:01 PM logoCommit To Buy Myriad Genetics At $15, Earn 10.3% Annualized Using Options - April 19 at 6:47 PM logoMyriad to Announce Fiscal Third-Quarter 2017 Financial Results on May 2, 2017 - GlobeNewswire (press release) - April 18 at 6:06 PM logoMyriad to Announce Fiscal Third-Quarter 2017 Financial Results on May 2, 2017 - April 18 at 6:06 PM logo Brokerages Expect Myriad Genetics, Inc. (MYGN) to Post $0.24 Earnings Per Share - April 18 at 9:40 AM logoMyriad Genetics, Inc. – Value Analysis (NASDAQ:MYGN) : April 17, 2017 - April 17 at 5:58 PM logoMyriad Genetics (MYGN) Says Study Finds Wide Gap in Quality of BRCA1/2 Variant Classification - April 17 at 10:02 AM logoStudy Finds Wide Gap in Quality of BRCA1/2 Variant Classification Between Myriad Genetics and A Common Public Database - April 17 at 10:02 AM logoMyriad Genetics (MYGN) Getting Somewhat Positive Press Coverage, Study Finds - April 16 at 2:35 PM logoShort Interest in Myriad Genetics, Inc. (MYGN) Declines By 5.7% - April 14 at 9:42 AM



Myriad Genetics (MYGN) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff